XML 50 R31.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information (Tables)
12 Months Ended
Dec. 31, 2024
Segment Information  
Schedule of Segment information

When evaluating the Company’s financial performance, the CODM regularly reviews the following expense categories that comprise net loss. The table below sets forth the Company’s segment information as reviewed by the CODM:

Year Ended December 31, 

2024

    

2023

Program expenses related to clinical-stage product candidates

$

(16,723,518)

$

(35,104,702)

Program expenses related to preclinical and discovery programs

(568,214)

(583,154)

Personnel-related expenses (including stock-based compensation)

(6,525,586)

(6,444,920)

General and administrative professional and consultant fees

(1,687,276)

(2,152,485)

Other segment items¹

(1,190,333)

(749,750)

Interest income

331,849

667,898

Other non-cash income (expense) items²

1,772,704

(11,837,199)

Net Loss

$

(24,590,374)

$

(56,204,313)

¹ Other segment items included in net loss include insurance expense, information technology expenses, warrant commissions and other miscellaneous expenses.

² Other non-cash income (expense) items includes financing costs from our ELOC and change in fair value of our liability classified warrants.